Comparison of PDE 4 inhibitors, rolipram and SB 207499 (Ariflo™, in a rat model of pulmonary neutrophilia

Pulmonary Pharmacology and Therapeutics

Volumn 14, Issue 2, 2001, Pages 157-164

  Spond, J ^a   Chapman, R ^a   Fine, J ^a   Jones, H ^a   Kreutner, W ^a   Kung, T T ^a   Minnicozzi, M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chronic bronchitis (COPD); LPS; Neutrophilia; Rolipram; SB 207499

Indexed keywords

CATECHOLAMINE; CILOMILAST; CORTICOSTEROID; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; LUNG LAVAGE; MALE; NEUTROPHILIA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RAT;

EID: 0034976397     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2001.0291     Document Type: Article

References (38)

1. Cellular mechanisms in the pathogenesis of COPD
2. ARDS-history, definitions and physiology
3. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis
4. Regulation of neutrophil activation in acute lung injury
5. The pathogenesis of chronic obstructive pulmonary disease
6. Chronic obstructive pulmonary disease: New opportunities for drug development
7. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma
8. Phosphodiesterase type IV inhibitors
9. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes
10. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils
11. 1,4-Cyclohexane carobylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma
12. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor α production by human mononuclear cells
13. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a low affinity phosphodiesterase 4 conformer
14. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition
15. Lung cytokines and ARDS
16. The role of anti-microbial therapy in acute exacerbations of chronic bronchitis
17. The association of circulating endotoxin with the development of the adult respiratory distress syndrome
18. Risk factors for lower airway bacterial colonization in chronic bronchitis
19. Inhibition of lipopolysaccharide-induced pulmonary edema by isoenzyme-selective phosphodiesterase inhibitors in guinea pigs
20. The intratracheal administration of endotoxin: X. Dexamethasone downregulates neutrophil emigration and cytokine expression in vivo
21. Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs
22. Alveolar neutrophils in endotoxin-induced and bacteria-induced acute lung injury in rats
23. Adrenalectomy permits a late, local TNF-α release in LPS-challenged rat airways
24. The intratracheal administration of endotoxin and cytokines
25. The therapeutic activity of SB 207499 (Airflo), a second-generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation
26. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase 4
27. Characterization of cAMP-dependent inhibition of LPS-induced TNF-α production by rolipram, a specific phosphodiesterase IV inhibitor
28. SB207499 (Airflo), a second-generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo
29. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents
30. Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung
31. Interrleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes
32. Appearance of cytokine induced neutrophil chemoattractant isoforms and immunolocalization of them in lipopolysaccharide induced lung inflammation in rats
33. Therapeutic intervention in a rat model of adult respiratory distress syndrome
34. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type 4 phosphodiesterase inhibitors
35. Regulation of tumor necrosis factor production by adrenal hormones in vivo: Insights into the anti-inflammatory activity of rolipram
36. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: Involvement of endogenously released corticosterone and catecholamines
37. Phosphodiesterase (PDE4) inhibitors: Anti-inflammatory drugs of the future
38. The efficacy of Airflo (SB 207499), a second generation, oral PDE4 inhibitor, in patients with COPD